Span-C-SBRT for Pancreatic Cancer (Span-C)
High Risk Localised Pancreatic Cancer
About this trial
This is an interventional treatment trial for High Risk Localised Pancreatic Cancer
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 and able to give informed consent
- Patients with histologically or cytologically confirmed locally advanced adenocarcinoma of the pancreas, including patients with extrapancreatic extension (Stage IIA), node positive (Stage IIB), borderline resectable or locally advanced as defined by AGITG guidelines
- ECOG performance status 0-1
- Measurable disease as defined by RECIST 1.1
- Have received or plan to receive chemotherapy
- Successful insertion of fiducial markers
Exclusion Criteria:
- Patients with metastatic pancreas cancer
- Prior abdominal radiotherapy
- Active malignancy excluding non melanomatous skin cancer
- Neuroendocrine pancreatic carcinoma
- Pregnant or lactating women
- Tumour size greater then 70mm
- Age >85
Sites / Locations
- Royal North Shore HospitalRecruiting
Arms of the Study
Arm 1
Experimental
Stereotactic Body Radiotherapy (SBRT)
Prior to SBRT, fiducial markers will be placed to aid with image guidance during radiation delivery. Fiducials will be inserted endoscopically (preferable) or intraoperatively. After this procedure, patients will have radiotherapy planning. During treatment, the fiducials will be used for registration with the images acquired during treatment (including kV fluoroscopy, MV or optical). The acquired images may be processed to determine fiducial location using KIM or MATT software from University of Sydney. SBRT 30-45Gray in 5 fractions will be given over 2 weeks. Four weeks after completion of SBRT participants will repeat a re-staging PET and CT scans. Those considered to be resectable will proceed to have surgery 6-10 weeks post SBRT.